Lilly’s Humalog U200, which delivers 200 units of insulin per milliliter, is for patients who need higher doses of insuling to control their diabetes, Billerica, Mass.-based Insulet said.
The deal calls for the companies to evaluate the use of Humalog U200 in the OmniPod insulin delivery system.
“We are thrilled to partner with Lilly to develop the first insulin pump specifically designed for Humalog U200 insulin,” CEO Patrick Sullivan said in prepared remarks. “This partnership allows Insulet to deliver the advantages of our OmniPod system to individuals worldwide with higher insulin requirements so they can better control their diabetes. Using Humalog U200 in OmniPod’s tubeless design effectively doubles the number of insulin units available to users in a single pod. This will provide the freedom and ease of use of our OmniPod System to a broader range of individuals living with diabetes.”